Cliff Asness AQR Capital Management
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.24% |
| 2 | Healthcare | 16.5% |
| 3 | Financials | 11.89% |
| 4 | Industrials | 11.49% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Markel Group
MKL
$22.2B
| $37.2M | 0.08% |
29,141
-35,871
| -55% | -$49.2M |
|
302
Darden Restaurants
DRI
$25.2B
| $37.2M | 0.08% |
331,305
+137,250
| +71% | +$17.1M |
|
303
RTX Corp
RTX
$283B
| $37.2M | 0.08% |
398,952
+218,795
| +121% | +$21M |
|
304
Grand Canyon Education
LOPE
$3.84B
| $37M | 0.08% |
394,101
+34,424
| +10% | +$3.21M |
|
|
ATVI
305
DELISTED
Activision Blizzard
ATVI
| $36.9M | 0.08% |
477,950
+12,148
| +3% | +$945K |
|
|
BERY
306
DELISTED
Berry Global Group, Inc.
BERY
| $36.9M | 0.08% |
736,099
+240,990
| +49% | +$12.5M |
|
307
Yelp
YELP
$1.27B
| $36.8M | 0.08% |
1,344,282
+97,453
| +8% | +$3.03M |
|
308
Unum
UNM
$13.9B
| $36.8M | 0.08% |
1,095,654
-182,042
| -14% | -$6.16M |
|
309
Nu Skin
NUS
$231M
| $36.5M | 0.08% |
849,131
+140,932
| +20% | +$6.47M |
|
310
Fortune Brands Innovations
FBIN
$5.32B
| $36.5M | 0.08% |
724,541
+191,515
| +36% | +$11.2M |
|
311
IPG Photonics
IPGP
$3.12B
| $36.4M | 0.08% |
390,119
+166,432
| +74% | +$16.4M |
|
312
Mohawk Industries
MHK
$9.23B
| $36.3M | 0.08% |
299,678
-53,974
| -15% | -$7.17M |
|
313
H&R Block
HRB
$6.62B
| $36.3M | 0.08% |
1,043,634
+873,787
| +514% | +$27M |
|
314
Revvity
RVTY
$13.9B
| $36.1M | 0.08% |
255,273
+17,731
| +7% | +$2.66M |
|
315
Keysight
KEYS
$53.8B
| $36.1M | 0.08% |
263,521
-90,305
| -26% | -$12.8M |
|
316
Pilgrim's Pride
PPC
$7.68B
| $36M | 0.08% |
1,155,615
+724,873
| +168% | +$21.3M |
|
317
IDEX
IEX
$17.3B
| $35.8M | 0.08% |
199,966
-12,729
| -6% | -$2.4M |
|
|
UNVR
318
DELISTED
Univar Solutions Inc.
UNVR
| $35.8M | 0.08% |
1,452,291
+339,217
| +30% | +$9.98M |
|
|
PACW
319
DELISTED
PacWest Bancorp
PACW
| $35.7M | 0.08% |
1,377,665
+918,847
| +200% | +$29.7M |
|
320
NCR Voyix
VYX
$1.09B
| $35.7M | 0.08% |
1,922,626
+963,536
| +100% | +$20.6M |
|
321
Corteva
CTVA
$54.6B
| $35.4M | 0.08% |
656,605
-481,308
| -42% | -$27.9M |
|
322
ACI Worldwide
ACIW
$5.24B
| $35.3M | 0.08% |
1,375,990
+253,521
| +23% | +$6.82M |
|
323
State Street
STT
$51.4B
| $34.5M | 0.08% |
568,605
+222,564
| +64% | +$15.7M |
|
324
Align Technology
ALGN
$11.5B
| $34.5M | 0.08% |
147,771
+68,522
| +86% | +$21.1M |
|
325
United Rentals
URI
$68.4B
| $34.4M | 0.08% |
144,393
+46,351
| +47% | +$13.6M |
|
Similar funds
Cliff Asness's Q2 2022 Portfolio in Review
As of Q2 2022, Cliff Asness held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Cliff Asness's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- Cliff Asness's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- Cliff Asness added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- Cliff Asness's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- Cliff Asness fully exited Roku in Q2 2022, selling an estimated $32.5M.
- Cliff Asness's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- Cliff Asness opened 150 new positions and closed 187 in Q2 2022.
- Cliff Asness's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.